Literature DB >> 31271030

Can Galactose Be Converted to Glucose in HepG2 Cells? Improving the in Vitro Mitochondrial Toxicity Assay for the Assessment of Drug Induced Liver Injury.

Qiuwei Xu1, Liping Liu1, Heather Vu1, Matthew Kuhls1, Amy G Aslamkhan1, Andy Liaw1, Yan Yu1, Allen Kaczor1, Michael Ruth1, Christina Wei1, John Imredy1, Jose Lebron1, Kara Pearson1, Raymond Gonzalez1, Kaushik Mitra1, Frank D Sistare1.   

Abstract

Human hepatocellular carcinoma cells, HepG2, are often used for drug mediated mitochondrial toxicity assessments. Glucose in HepG2 culture media is replaced by galactose to reveal drug-induced mitochondrial toxicity as a marked shift of drug IC50 values for the reduction of cellular ATP. It has been postulated that galactose sensitizes HepG2 mitochondria by the additional ATP consumption demand in the Leloir pathway. However, our NMR metabolomics analysis of HepG2 cells and culture media showed very limited galactose metabolism. To clarify the role of galactose in HepG2 cellular metabolism, U-13C6-galactose or U-13C6-glucose was added to HepG2 culture media to help specifically track the metabolism of those two sugars. Conversion to U-13C3-lactate was hardly detected when HepG2 cells were incubated with U-13C6-galactose, while an abundance of U-13C3-lactate was produced when HepG2 cells were incubated with U-13C6-glucose. In the absence of glucose, HepG2 cells increased glutamine consumption as a bioenergetics source. The requirement of additional glutamine almost matched the amount of glucose needed to maintain a similar level of cellular ATP in HepG2 cells. This improved understanding of galactose and glutamine metabolism in HepG2 cells helped optimize the ATP-based mitochondrial toxicity assay. The modified assay showed 96% sensitivity and 97% specificity in correctly discriminating compounds known to cause mitochondrial toxicity from those with prior evidence of not being mitochondrial toxicants. The greatest significance of the modified assay was its improved sensitivity in detecting the inhibition of mitochondrial fatty acid β-oxidation (FAO) when glutamine was withheld. Use of this improved assay for an empirical prediction of the likely contribution of mitochondrial toxicity to human DILI (drug induced liver injury) was attempted. According to testing of 65 DILI positive compounds representing numerous mechanisms of DILI together with 55 DILI negative compounds, the overall prediction of mitochondrial mechanism-related DILI showed 25% sensitivity and 95% specificity.

Entities:  

Year:  2019        PMID: 31271030     DOI: 10.1021/acs.chemrestox.9b00033

Source DB:  PubMed          Journal:  Chem Res Toxicol        ISSN: 0893-228X            Impact factor:   3.739


  4 in total

1.  The critical size of gold nanoparticles for overcoming P-gp mediated multidrug resistance.

Authors:  Yuqian Jiang; Zheng Wang; Wei Duan; Lingyan Liu; Mahan Si; Xiaoyuan Chen; Chen-Jie Fang
Journal:  Nanoscale       Date:  2020-06-17       Impact factor: 7.790

2.  Application of a Rat Liver Drug Bioactivation Transcriptional Response Assay Early in Drug Development That Informs Chemically Reactive Metabolite Formation and Potential for Drug-induced Liver Injury.

Authors:  James J Monroe; Keith Q Tanis; Alexei A Podtelezhnikov; Truyen Nguyen; Sam V Machotka; Donna Lynch; Raymond Evers; Jairam Palamanda; Randy R Miller; Todd Pippert; Tamara D Cabalu; Timothy E Johnson; Amy G Aslamkhan; Wen Kang; Alex M Tamburino; Kaushik Mitra; Nancy G B Agrawal; Frank D Sistare
Journal:  Toxicol Sci       Date:  2020-09-01       Impact factor: 4.849

3.  Aglycemic growth enhances carbohydrate metabolism and induces sensitivity to menadione in cultured tumor-derived cells.

Authors:  Cameron A Schmidt; Kelsey L McLaughlin; Ilya N Boykov; Rafiq Mojalagbe; Arthi Ranganathan; Katherine A Buddo; Chien-Te Lin; Kelsey H Fisher-Wellman; P Darrell Neufer
Journal:  Cancer Metab       Date:  2021-01-19

4.  Mechanistic Investigations Support Liver Safety of Ubrogepant.

Authors:  Brenda Smith; Josh Rowe; Paul B Watkins; Messoud Ashina; Jeffrey L Woodhead; Frank D Sistare; Peter J Goadsby
Journal:  Toxicol Sci       Date:  2020-09-01       Impact factor: 4.849

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.